TNYAライブシグナル | Getagraph.comで利益を最大化

売る 108129 min ago

@ $5.35

発行日: 14 2月 2024 @ 23:30

リターン: -13.64%

前回のシグナル: 2月 13 - 01:24

前回のシグナル: 買う

リターン: -6.14 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:23):

Stats
本日の出来高	60 308.00
平均出来高	531 553
時価総額	362.74M
EPS	$-0.390 ( 2024-03-20 )
次の収益日	( $-0.430 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.75
ATR14	$0.0120 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Hoey Timothy	Sell	3 300	Common Stock
2024-02-23	Hoey Timothy	Buy	12 500	Common Stock
2024-02-23	Hoey Timothy	Buy	75 000	Stock Option (Right to buy)
2024-02-23	Tingley Whittemore	Buy	215 000	Stock Option (Right to buy)
2024-02-23	Tingley Whittemore	Buy	35 000	Common Stock

INSIDER POWER
99.36
Last 96 transactions
Buy: 62 840 535 \| Sell: 9 767 330

ボリューム相関

長: -0.13 (neutral)

短: 0.40 (neutral)

Signal:(78.703) Neutral

Tenaya Therapeutics, Inc. 相関

10 最も正の相関
MDRR	0.829
RESN	0.81

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Tenaya Therapeutics, Inc. 相関 - 通貨/商品

-0.89
( strong negative )

-0.90
( strong negative )

0.00
( neutral )

-0.84
( strong negative )

-0.28
( neutral )

0.80
( moderate )

Tenaya Therapeutics, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-8.69M (0.00 %)
EPS:	$-1.680

FY	2023
収益:	$0
総利益:	$-8.69M (0.00 %)
EPS:	$-1.680

FY	2022
収益:	$0
総利益:	$-8.71M (0.00 %)
EPS:	$-2.76

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00269

Financial Reports:

No articles found.

Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.